The RELIEF trial

The RELIEF trial

UPDATED - [July 2023]

Randomised controlled trial of a new relief inhaler in mild asthma.

Inclusion & Exclusion Criteria

Inclusion

1. Patients aged 18 and over with a clinical diagnosis of mild asthma*

2. Treated with low dose ICS**

3. Prescribed 11 or fewer canisters of Salbutamol in the last 12 months***

4. Ability to provide written informed consent

*For the purposes of this trial “mild asthma” is defined as those patients with an existing clinical diagnosis of asthma (recorded in medical records) and treated with either a Salbutamol alone or low dose ICS and Salbutamol. No further diagnostic tests will be undertaken to confirm asthma or its severity as we want the trial to be pragmatic in nature and, therefore, include patients who are currently treated for mild asthma. 

**low dose ICS is defined as up to and including 400 mcg BDP/day or equivalent

***Patients using Salbutamol alone and using 3 or more inhalations per week can be included if started on low dose ICS as part of their routine care before trial commencement.

Exclusion 

1. Salbutamol used only to prevent exercise induced asthma.

2. Other respiratory or non-respiratory diagnosis which will affect the trial interpretation in the view of the investigator (this includes, but is not limited to, smoking related Chronic Obstructive Pulmonary Disease (COPD) and clinically significant bronchiectasis).

3. Participants who are pregnant or who are intending to become pregnant

Study Resources

Access for the SystmOne and EMIS study resources can be requested below.

For further guidance on using the resources, please refer to the guidance documents and further useful information on the PRIDES page.

If you have any questions about using the resources provided or would like to be involved in the development of future resources please get in touch through the Contact Page.

Disclaimer:

Please note the resources provided are designed to assist with the identification of potentially suitable patients and to appropriately code these patient if required.

These resources have been developed based on the criteria provided by the relevant study team and whilst every effort has been made to make them universally implementable they rely on read codes and the data stored in the individual practice's clinical system. These resources are intended to assist with identification but should be used in conjunction with clinical oversight and a clear understanding of the study parameters.

While we endeavour to keep the information, tools and resources provided up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the tools provided for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of the tools provided.

Optional text: 

All resources include base exclusion search. This search excludes all patients who;

• have a read-code for receiving palliative care or are on the GSF (Gold Standards Framework)

• Have a read-coded diagnosis of cancer

The above are excluded prior to any search exclusion unless one of the above is a target group. If you would prefer not to exclude these groups be default please review the instructions here.